Navigation Links
Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
Date:3/4/2013

psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine, USP) HD, FazaClo LD, and Luvox CR® (fluvoxamine maleate). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the public offering of ordinary shares of Jazz Pharmaceuticals. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the public offering. Additional risks and uncertainties relating to the public offering, Jazz Pharmaceuticals and its business can be found under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including in its Annual Report on Form 10-K for the year ended December 31, 2012. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

 


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
2. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
3. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
4. AVANIR Pharmaceuticals To paticipate in two conferences in March
5. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
6. Adamis Pharmaceuticals Prevails in License Dispute Litigation
7. Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
8. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
9. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
10. StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
11. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, ... Tobago Ministry of Health approved the introduction of ... increases the cure rate from Hepatitis C, and ... genotype 1 virus. Telaprevir is available in ... INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... 25, 2014  Acsis Inc., the market leader ... solutions, has recently posted an article, "Future ... and future needs for companies, extended supply chain, ... chain model no longer work today.  The article ... growth of mobile technology, machine to machine (M2M) ...
(Date:7/25/2014)... 25, 2014 According to a ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, ... Growth, Trends and Forecast (Value and Volume), 2013 - ... 19.99 billion in 2012 and is expected to grow ... to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
(Date:7/27/2014)... July 27, 2014 The European Agricultural ... in Europe with analysis and forecast of revenue. The ... from around $509.4 million in 2013 to $657.1 million ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. It also provides a ...
(Date:7/27/2014)... 27, 2014 Metachromatic leukodystrophy (MLD, ... storage disease which is commonly listed in the ... sphingolipidoses as it affects the metabolism of sphingolipids. ... the fatty covering which acts as an insulator ... nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 One of the ... genomics products from the Asia Pacific (APAC) region. The Diagnostics ... to generate high demand for genomics solutions, thereby contributing to ... will grow at a CAGR of 11.21 percent over ... driver of the market is an increase in the demand ...
(Date:7/27/2014)... 2014 Alta Resources , a ... for Fortune 500 brands, announced today that it plans ... in Wisconsin, California, Florida and the Philippines. , A ... clients, which have seasonal ramp-ups that require additional staffing ... 2014 through February 2015. As more consumers become eligible ...
(Date:7/27/2014)... 27, 2014 Wright & Schulte LLC ... filed a GranuFlo lawsuit against Fresenius Medical Care ... over the recalled dialysis drugs GranuFlo and NaturaLyte. The ... by not disclosing the heart attack risks associated with ... Fresenius notified its own clinics, practitioners and physicians about ...
Breaking Medicine News(10 mins):Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 2Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 3Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 4Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 5Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 2Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 3Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 4Health News:Louisiana Files GranuFlo Lawsuit Against Fresenius Medical Care over Its Recalled GranuFlo and NaturaLyte Dialysis Drugs 5
... of Chemicals, has shifted the burden or responsibility of handling ... would be bound by law to make use of only ... law aims to make chemicals used in all products ; ... ,The European Parliament has approved this legislation on ...
... plausible culprit for rendering sick nearly 260 Tewksbury students, ... stomach virus// has allegedly gripped several of the students ... not about to spare anyone- teachers, parents and siblings ... us to keep everything clean,” said Sue McLaughlin, co-chairwoman ...
... for ovarian cancer are at increased risk of a ... have high// levels of a binding protein that triggers ... of malignancy. ,“Now there’s the possibility that ... surgery might identify women most at risk for recurrence ...
... symptoms, including enlarged or painful breast tissue, but the ... Mayo Clinic Cancer Center. // Mammograms are used to ... very rare in males. ,Their study, presented Saturday, ... Antonio Breast Cancer Symposium, suggests physicians should reconsider ordering ...
... vaccine against HIV/AIDS, the 'social vaccine' of mass awareness needs ... a top UN official here said Saturday. // ... HIV/AIDS," said Peter Piot, executive director of United Nations Programme ... create a mass awareness to educate the people about the ...
... followed the discovery of neural stem cells and their potential ... spinal cord//, recent research identified “cancer stem cells,” a small ... cells comprising a malignant brain tumor. Theoretically, if these mother ... to sustain itself. On the other hand, if these cells ...
Cached Medicine News:Health News:'Clumping' Protein Linked to Return of Ovarian Cancer 2Health News:Use of Mammograms in Men 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 3
The Deluxe Knee Immobilizer provides superb lightweight immobilization following injury or surgery. It is available in a wide array of sizes for excellent comfort and fit....
... and Defiance III is DonJoy's hallmark knee ... and design, this lightweight brace provides durable ... MCL and LCL instabilities. Plus, the low-profile ... uniforms, including hockey and football. As the ...
Provides range-of-motion control for both flexion and extension along with a drop lock feature...
Dynamic brace that provides a low load, prolonged stretch to the connective tissue around the joint using an adjustment hinge with a built-in tension spring...
Medicine Products: